However 50% of patients with HER2-positive breast cancer show immunotherapy resistance to anti-HER2 monoclonal antibodies, being the use of TK inhibitors (TKi) an alternative approach for these targeted immunotherapies. Here, TKT is linked to breast carcinoma.